The U.S.
Food and Drug Administration (FDA) approved on Wednesday Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Tryngolza (olezarsen) to treat severe hypertriglyceridemia. • Ionis Pharmaceuticals stock is moving in positive territory.
Why are IONS shares climbing?
The company also struck a global licensing agreement with Italy-based Recordati for its investigational Alexander disease therapy, zilganersen, outside the U.S.
The developments bolster Ionis' commercial portfolio as it prepares for a potential U.S. launch of zilganersen later this year.
